Patents Assigned to GLUCOX BIOTECH AB
  • NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY
    Publication number: 20250136545
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase 4 or 2 (Nox4 or Nox2) activity. A pharmaceutical composition comprising the compound.
    Type: Application
    Filed: December 11, 2024
    Publication date: May 1, 2025
    Applicant: GLUCOX BIOTECH AB
    Inventors: Per WIKSTRÖM, Erik WALUM
  • Sulfonamide derivatives having selective Nox inhibiting activity
    Patent number: 12202790
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase 4 or 2 (Nox4 or Nox2) activity. A pharmaceutical composition comprising the compound.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: January 21, 2025
    Assignee: GLUCOX BIOTECH AB
    Inventors: Per Wikström, Erik Walum
  • Compounds for use in the treatment of conditions associated with NADPH oxidase
    Patent number: 10195167
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: February 5, 2019
    Assignee: Glucox Biotech AB
    Inventors: Per Wikström, Erik Walum, Mona Wilcke
  • N-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine
    Patent number: 10173988
    Abstract: The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine or a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase activity. A pharmaceutical composition comprising the compound.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: January 8, 2019
    Assignee: GLUCOX BIOTECH AB
    Inventors: Per Wikström, Erik Walum, Mona Wilcke
  • Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase
    Patent number: 9687490
    Abstract: A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: June 27, 2017
    Assignee: GLUCOX BIOTECH AB
    Inventors: Mona Wilcke, Erik Walum, Per Wikstrom
  • COMPOUNDS FOR USE IN THERAPY
    Publication number: 20150051220
    Abstract: A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: GLUCOX BIOTECH AB
    Inventors: Mona Wilcke, Erik Walum, Per Wikstrom